



Docket No.: 00630/100G184-US1
(PATENT)

Customer No.:



Patent & Trademark Office

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Suzana Petanceska et al.

Application No.: 09/695,446

Confirmation No.: 2608

Filed: October 24, 2000

Art Unit: 1615

For: METHODS FOR IDENTIFYING AND
USING AMYLOID-INHIBITORY
COMPOUNDS

Examiner: Liliana Di Nola Baron

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

08/13/2004 MNEKONEN 00000031 09695446

02 FC:1806

180.00 OP

{W:\00630\100G184US1\00219782.DOC [REDACTED]}

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

A copy of each document on the PTO/SB/08 is attached.

A concise explanation of relevance of the items listed on form PTO/SB/08 is given.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.


Our check in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is enclosed. The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: August 10, 2004

Respectfully submitted,

By Kristin E. Behrendt
Kristin E. Behrendt

Registration No.: 45,599
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 753-6237 (Fax)
Attorneys/Agents For Applicant



32801

PATENT TRADEMARK OFFICE

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/695,446	
			Filing Date	October 24, 2000	
			First Named Inventor	Suzana Petanceska	
			Art Unit	1615	
			Examiner Name	Liliana Di Nola Baron	
Sheet	1	of	2	Attorney Docket Number	00630/100G184-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1.	Sally A. Shumaker, PhD et al., "Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women" American Medical Assoc., Jama, Vol.291, No.24, pgs. 2947-2958, 2004	
	2.	Mark A. Espeland, PhD et al., "Conjugated Equine Estrogens and Global Cognitive Function in Postmenopausal Women" American Medical Assoc., Jama, Vol. 291, No. 24, pgs. 2959-2968, 2004	
	3.	V.W. Henderson, MD et al. "Estrogen for Alzheimer's disease in women" American Academy of Neurology, pgs. 295-301, Vol. 54, January 2000	
	4.	Ruth A. Mulnard, et al., "Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease" American Medical Assoc., Jama, Vol. 283, No.283, Nos. 8, 20 pgs.1007-2597, 2000	
	5.	Peter R. Rapp, et al., "Cyclic Estrogen Replacement Improves Cognitive Function in Aged Ovariectomized Rhesus Monkeys", The Journal of Neuroscience (2003), Vol. 23 pgs. 5708-5714	
	6.	Justine A. Levin-Allerhand, et. al., "17 α -estradiol and 17 β -estradiol treatments are effective in lowering cerebral amyloid- β levels in A β PPSWE transgenic mice, Journal of Alzheimer's Disease 4 (2002) pgs. 449-457	
	7.	T. Heikkinen et al., "Estrogen treatment improves spatial learning in APP + PS1 mice but does not affect beta amyloid accumulation and plaque formation", Experimental Neurology, Vol. 187 (2004) pgs. 105-117	
	8.	Peter P. Zandi, PhD et al., "Hormone Replacement Therapy and Incidence of Alzheimer Disease in Older Women" American Medical Assoc (2002), Jama, Vol. 288, No. 17, pgs.2123-2129	

W:006 30/100	Date Considered
-----------------	-----------------



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/695,446
				Filing Date	October 24, 2000
				First Named Inventor	Suzana Petanceska
				Art Unit	1615
				Examiner Name	Liliana Di Nola Baron
Sheet	2	of	2	Attorney Docket Number	00630/100G184-US1

9.	Susan M. Resnick, PhD et al., "Hormone Therapy and Risk of Alzheimer Disease" American Medical Assoc. (2002), Jama, Vol. 288, No. 17, pgs. 2170-2172	
10.	Mark A. Smith, Ph.D. et al, "Estrogen Replacement and Risk of Alzheimer Disease", American Medical Assoc. (2003), Jama, Vol. 289, No. 9, pgs 1100-1102	
11.	E. M. Johnstone et al., "Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis" (1991) Molec. Brain Resh., Vol. 10, pgs 299-305.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

W:006 30/100		Date Considered	
-----------------	--	--------------------	--